X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KET01 is an oral prolonged-release ketamine formulation, a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia typically in combination with a muscle relaxant. It is being currently developed for treatment-resistant depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: KET01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Develco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Details:
BH-200 (nelivaptan) is a potent vasopressin V1b receptor antagonist, for improved treatment of patients with MDD who have underlying HPA-axis (Hypothalamus‐pituitary‐adrenal axis) dysfunction.
Lead Product(s): Nelivaptan
Therapeutic Area: Psychiatry/Psychology Product Name: BH-200
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
KET01 is an oral prolonged-release ketamine formulation, a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia typically in combination with a muscle relaxant. It is being currently developed for treatment-resistant depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Ketabon
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Develco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
The trial will assess the efficacy, safety, and tolerability of add-on treatment with Ketamine hydrochloride prolonged-release tablets (KET01) in patients suffering from Treatment-Resistant depression (TRD).
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: KET01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
Data suggest that KET01 is rapidly acting with a clinically meaningful improvement compared with placebo already after 7 days, which stands in sharp contrast to standard antidepressants which have a delayed onset of action of up to several weeks.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: KET01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Develco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
HMNC and Develco Pharma have created a joint venture and formed the company Ketabon, which will initiate a Contract Research Organization led proof-of-concept study of an investigational oral prolonged-release formulation of ketamine targeting treatment-resistant depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Develco Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
